Recently, the U.S. National Institutes of Health (NIH) and Food and Drug Administration (FDA) called for the eliminating involvement of the Recombinant DNA Advisory Committee (RAC) in human gene therapy experiments, marking the end of an era of federal government oversight. While the RAC played an essential role in helping human gene therapy research evolve to where it is today, James M. Wilson, MD, Ph.D., Editor, Human Gene Therapy Clinical Development, believes this is the right moment for it to exit the stage, as he explains in his Editorial “The RAC Retires After a Job Well Done,” Human Gene Therapy Clinical Development.
The RAC initially set guidelines for DNA research, and its role was later expanded to en-compass the review and approval of human gene therapy research. The Committee was composed of stakeholders, including basic scientists, physicians, ethicists, theologians, and patients advocates. “The deliberations often became theatrical and, at times, quite contentious,” says Dr. Wilson. Over the years, as the field of human gene therapy ma-tured and became more integrated into the biopharmaceutical industry the potential re-dundancies between the roles of the FDA and the RAC became an increasingly important issue.
Source: Read Full Article